Multi-year share price forecasts for clinical-stage biotechnology firms like GT Biopharma, Inc. (NASDAQ: GTBP) are speculative and depend heavily on binary clinical trial readouts, successful capitalization rounds, and regulatory updates regarding its TriSpecific killer cell engager immunotherapy platform. Trading at micro-cap levels around $0.28 to $0.30, future valuations remain tightly bound to upcoming pipeline execution milestones rather than traditional cash-flow models.